Trial · NCT03427411
Adverse events630
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 630
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Abdominal pain | Gastrointestinal disorders | Participants Naïve to Checkpoint Inhibition - M7824 1,200 mg Intravenous Once Every 2 Weeks | 8 | 30 | 11 |
| other | Abdominal pain | Gastrointestinal disorders | Participants Refractory to Checkpoint Inhibition - M7824 1,200 mg Intravenous Once Every 2 Weeks | 7 | 26 | 10 |
| other | Adrenal insufficiency | Endocrine disorders | Participants Naïve to Checkpoint Inhibition - M7824 1,200 mg Intravenous Once Every 2 Weeks | 2 | 30 | 2 |
| other | Adrenal insufficiency | Endocrine disorders | Participants Refractory to Checkpoint Inhibition - M7824 1,200 mg Intravenous Once Every 2 Weeks | 0 | 26 | 0 |
| other | Agitation | Psychiatric disorders | Participants Naïve to Checkpoint Inhibition - M7824 1,200 mg Intravenous Once Every 2 Weeks | 0 | 30 | 0 |
| other | Agitation | Psychiatric disorders | Participants Refractory to Checkpoint Inhibition - M7824 1,200 mg Intravenous Once Every 2 Weeks | 2 | 26 | 2 |
| other | Alanine aminotransferase increased | Investigations | Participants Naïve to Checkpoint Inhibition - M7824 1,200 mg Intravenous Once Every 2 Weeks | 4 | 30 | 5 |
| other | Alanine aminotransferase increased | Investigations | Participants Refractory to Checkpoint Inhibition - M7824 1,200 mg Intravenous Once Every 2 Weeks | 4 | 26 | 4 |
| other | Alkaline phosphatase increased | Investigations | Participants Naïve to Checkpoint Inhibition - M7824 1,200 mg Intravenous Once Every 2 Weeks | 1 | 30 | 1 |
| other | Alkaline phosphatase increased | Investigations | Participants Refractory to Checkpoint Inhibition - M7824 1,200 mg Intravenous Once Every 2 Weeks | 4 | 26 | 4 |
| other | Allergic reaction | Immune system disorders | Participants Naïve to Checkpoint Inhibition - M7824 1,200 mg Intravenous Once Every 2 Weeks | 1 | 30 | 1 |
| other | Allergic reaction | Immune system disorders | Participants Refractory to Checkpoint Inhibition - M7824 1,200 mg Intravenous Once Every 2 Weeks | 0 | 26 | 0 |
| other | Allergic rhinitis | Respiratory, thoracic and mediastinal disorders | Participants Naïve to Checkpoint Inhibition - M7824 1,200 mg Intravenous Once Every 2 Weeks | 1 | 30 | 1 |
| other | Allergic rhinitis | Respiratory, thoracic and mediastinal disorders | Participants Refractory to Checkpoint Inhibition - M7824 1,200 mg Intravenous Once Every 2 Weeks | 0 | 26 | 0 |
| other | Alopecia | Skin and subcutaneous tissue disorders | Participants Naïve to Checkpoint Inhibition - M7824 1,200 mg Intravenous Once Every 2 Weeks | 1 | 30 | 1 |
| other | Alopecia | Skin and subcutaneous tissue disorders | Participants Refractory to Checkpoint Inhibition - M7824 1,200 mg Intravenous Once Every 2 Weeks | 1 | 26 | 1 |
| other | Anal hemorrhage | Gastrointestinal disorders | Participants Naïve to Checkpoint Inhibition - M7824 1,200 mg Intravenous Once Every 2 Weeks | 2 | 30 | 3 |
| other | Anal hemorrhage | Gastrointestinal disorders | Participants Refractory to Checkpoint Inhibition - M7824 1,200 mg Intravenous Once Every 2 Weeks | 0 | 26 | 0 |
| other | Anemia | Blood and lymphatic system disorders | Participants Naïve to Checkpoint Inhibition - M7824 1,200 mg Intravenous Once Every 2 Weeks | 19 | 30 | 44 |
| other | Anemia | Blood and lymphatic system disorders | Participants Refractory to Checkpoint Inhibition - M7824 1,200 mg Intravenous Once Every 2 Weeks | 19 | 26 | 53 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03427411/events